Rivulet Media Inc (fka RIVU)

[xdelivery21]

HemaXellerate I™ is BMSN’s stem cell drug to combat Aplastic Anemia. Aplastic Anemia is eligible for Orphan Drug Status which makes HemaXellerate I™ able to get full FDA approval in as little as 60 days to bypass the lengthy Phase I, II, III, IV FDA Approval Processes because of being eligible for Orphan Drug Status. This is because HemaXellerate I™ has been confirmed to be something special enough to save the lives of people who have been diagnosed with Aplastic Anemia which could lead to rapid death. Read below to learn more about the Orphan Drug Designation: